Is roseola exposure safe during pregnancy?

What does the evidence say about roseola exposure during pregnancy?

1. An NCBI clinical review reports that more than 95 percent of adults are seropositive for HHV-6 and that the virus remains latent after primary infection. High background seropositivity makes a first infection in pregnancy less common, but it does not prove that every exposed person is immune. 1
2. A 1992 report described one pregnant adult with primary roseola and stated that fetal risk was unknown. A single case without a comparison group cannot estimate miscarriage, malformation, growth, or preterm-birth risk. 2
3. A reproductive review reports HHV-6 DNA in about 1 to 2 percent of newborns, most often from inherited chromosomally integrated virus rather than a newly acquired maternal roseola infection. Congenital viral DNA therefore cannot be used as evidence that casual childhood exposure caused fetal infection. 3
4. In a cohort of 104 pregnant participants and 31 nonpregnant controls, investigators detected HHV-6 DNA in blood or cervical samples and reported one active placental infection with congenital transmission. Detection did not establish clinical roseola, fetal harm, or causation, and the comparison group was small. 4
5. MedlinePlus describes roseola as a childhood illness spread through respiratory droplets or saliva, usually with several days of high fever followed by a rash. These features help define exposure, but they do not confirm the cause of fever or rash in a pregnant adult. 5

Is roseola exposure safe in each trimester?

• First trimester. Early pregnancy is a reason to report a new fever or rash promptly because several infections can look alike and some have clearer fetal implications than roseola. A child's roseola label does not establish that a pregnant adult's illness is HHV-6.
• Second trimester. Most adults have prior HHV-6 antibodies, but seropositivity does not identify the cause of a new rash. Record exposure dates and symptoms, and let the obstetric team decide whether another infection needs testing.
• Third trimester. Near delivery, alert the maternity team to active fever, rash, or systemic illness. Available HHV-6 studies do not define a special delivery plan after uncomplicated exposure alone, so decisions should follow maternal symptoms and obstetric findings.